| Therapeutic | Zenocutuzumab |
| Target 1 | ERBB3/HER3 |
| Heavy Chain 1 | QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS |
| Light Chain 1 | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK |
| 100% seqID Fv 1 Structure | 5o4o [Fvs: BA], 5o7p [Fvs: BA] |
| 99% seqID Fv 1 Structure | None |
| 95-98% seqID Fv 1 Structure | None |
| Target 2 | ERBB2/CD340/HER2 |
| Heavy Chain 2 | QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS |
| Light Chain 2 | DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK |
| 100% seqID Fv 2 Structure | 5o4g [Fvs: BA] |
| 99% seqID Fv 2 Structure | None |
| 95-98% seqID Fv 2 Structure | None |
| 100% seqID Structure [Fv 1] | 5o4o [Fvs: BA] |
| 100% seqID Structure [Fv 1] | 5o7p [Fvs: BA] |
| 100% seqID Structure [Fv 2] | 5o4g [Fvs: BA] |
Follow these links to our prediction tools:
| Format | Bispecific mAb |
| Isotype | G1;G1 |
| Highest Clinical Trial (Feb '25) | Approved |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | GlymaxX Technology |
| INN Year Proposed | 2017 |
| INN Year Recommended | 2018 |
| Companies Involved | Merus |
| Conditions Approved | Adenocarcinoma, Non-small cell lung cancer |
| Conditions Active | HER2 positive breast cancer, Prostate cancer, Solid tumours, Cancer |
| Conditions Discontinued | |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
